| Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge | Clinical Chemistry | 1972 | 22.5K |
| Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | JAMA - Journal of the American Medical Association | 2001 | 21.5K |
| Atherosclerosis--an inflammatory disease | New England Journal of Medicine | 1999 | 17.3K |
| Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement | Circulation | 2005 | 8K |
| Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge | Clinical Chemistry | 1972 | 7.5K |
| Prediction of coronary heart disease using risk factor categories | Circulation | 1998 | 6.8K |
| MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial | Lancet, The | 2002 | 6.6K |
| Inflammation in atherosclerosis | Nature | 2002 | 6.5K |
| Inflammation, atherosclerosis, and coronary artery disease | New England Journal of Medicine | 2005 | 6.3K |
| Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group | New England Journal of Medicine | 1995 | 6.3K |
| Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | New England Journal of Medicine | 2015 | 6.1K |
| The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators | New England Journal of Medicine | 1996 | 6.1K |
| Structure-antioxidant activity relationships of flavonoids and phenolic acids | Free Radical Biology and Medicine | 1996 | 6K |
| Inflammation and atherosclerosis | Circulation | 2002 | 5.2K |
| Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction | New England Journal of Medicine | 1998 | 5.2K |
| Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity | New England Journal of Medicine | 1989 | 5.1K |
| Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins | Lancet, The | 2005 | 5.1K |
| Polyphenols: food sources and bioavailability | American Journal of Clinical Nutrition | 2004 | 5K |
| A receptor-mediated pathway for cholesterol homeostasis | Science | 1986 | 4.7K |
| C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women | New England Journal of Medicine | 2000 | 4.6K |
| Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines | Circulation | 2004 | 4.5K |
| Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group | JAMA - Journal of the American Medical Association | 1998 | 4.2K |
| High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study | American Journal of Medicine | 1977 | 4.1K |
| Atherosclerosis | Nature | 2000 | 4K |
| Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials | Lancet, The | 2010 | 3.8K |
